Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radiant SetPoint

This article was originally published in The Gray Sheet

Executive Summary

Endovascular temperature management catheter's 510(k) clearance for use in surgery and critical care is the first of its kind, the firm maintains June 12. The device controls patient blood temperature during cardiac surgery and post-operative intensive care. An acute myocardial infarction indication is expected in the first half of 2003, based on a 400-patient, 25-center clinical study (1"The Gray Sheet" Feb. 25, 2002, p. 5)...

You may also be interested in...



Alsius, Radiant, InnerCool Heat Up Hypothermia Market Competition

Alsius Corp. expects to be the first to market with an intravascular temperature management system for controlling fever in the neuro-critical care setting, pending FDA clearance of a December 2001 510(k) submission

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.

CMS Removes Some Stark Law ‘Bureaucratic Barriers’ In Final Rule

The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel